NCT05058638

Effectiveness of Aquamin® in Mitigating Halitosis

Evaluation of Halitosis Using a Multi-Mineral Approach (Aquamin®)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.

Detailed description

This is a sub-study to the ongoing clinical trial entitled: Aquamin®, a multi-mineral natural product from red marine algae, as an adjuvant intervention for mild ulcerative colitis and ulcerative colitis in remission (HUM00156676) NCT# NCT03869905. However, the Food and Drug Administration (FDA) indicated that no Investigational New Drug Application (IND) was required.

Conditions

• Healthy
• Halitosis

Interventions

Type	Name	Description
DRUG	Aquamin	Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).

Timeline

• Start date: 2022-08-15
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2021-09-28
• Last updated: 2026-01-20

Locations

1 site across 1 country: United States